These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 590978)

  • 41. [Behavior of 125-I-fibrinogen and 131-I-albumin in experimental galactosamine hepatitis].
    von Mahn I; Merkel H; Sattler EL; Müller-Berghaus G
    Verh Dtsch Ges Inn Med; 1974; 80():437-9. PubMed ID: 4454578
    [No Abstract]   [Full Text] [Related]  

  • 42. Induction of tyrosine aminotransferase in galactosamine hepatitis.
    Pugge HR; Torrecilla A; Pellanda RJ
    Acta Gastroenterol Latinoam; 1979; 9(3):159-63. PubMed ID: 43646
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Influence of liver-RES on toxic liver damage due to galactosamine.
    Grün M; Liehr H; Grün W; Rasenack U; Brunswig D
    Acta Hepatogastroenterol (Stuttg); 1974 Feb; 21(1):5-15. PubMed ID: 4450963
    [No Abstract]   [Full Text] [Related]  

  • 44. [The incorporation of essential phospholipids into the organs of intact and galactosamine intoxicated rats].
    Lekim D; Betzing H
    Arzneimittelforschung; 1974 Aug; 24(8):1217-21. PubMed ID: 4479326
    [No Abstract]   [Full Text] [Related]  

  • 45. Hepatic blood flow in rats with galactosamine hepatitis.
    Liehr H; Grün M; Thiel H; Krauss H; Rost R
    Acta Hepatogastroenterol (Stuttg); 1972; 19(4):259-63. PubMed ID: 4663715
    [No Abstract]   [Full Text] [Related]  

  • 46. Proceedings: The hepatotoxic effect of ethanol after pretreatment with carbon tetrachloride, allyl alcohol, or D-galactosamine.
    Strubelt O; Buettner F; Siegers CP
    Naunyn Schmiedebergs Arch Pharmacol; 1975; 287 Suppl():R102. PubMed ID: 1170506
    [No Abstract]   [Full Text] [Related]  

  • 47. Galactosamine- "hepatitis" in rats with different phagocytic activity of liver RES.
    Rasenack U; Grün M; Liehr H
    Acta Hepatogastroenterol (Stuttg); 1975 Feb; 22(1):29-35. PubMed ID: 1119301
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Glycine and uridine prevent D-galactosamine hepatotoxicity in the rat: role of Kupffer cells.
    Stachlewitz RF; Seabra V; Bradford B; Bradham CA; Rusyn I; Germolec D; Thurman RG
    Hepatology; 1999 Mar; 29(3):737-45. PubMed ID: 10051475
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Liver tissue enzymes in rats with galactosamine hepatitis during simultaneous administration of choline-orotate].
    Petzold H
    Cesk Gynekol; 1973 Jul; 27(5):290-3. PubMed ID: 4269483
    [No Abstract]   [Full Text] [Related]  

  • 50. [Function of lysosomal enzymes in galactosamine hepatitis].
    Heissmeyer H; Stein U
    Verh Dtsch Ges Inn Med; 1972; 78():1377-80. PubMed ID: 4665551
    [No Abstract]   [Full Text] [Related]  

  • 51. [Primary and secondary liver response to D-galactosamine administration in galactosamine hepatitis].
    Reutter W; Bauer C; Bachman W; Lesch R
    Verh Dtsch Ges Inn Med; 1973; 79():927-30. PubMed ID: 4790045
    [No Abstract]   [Full Text] [Related]  

  • 52. Halothane hepatitis revisited.
    Barash PG; Greene NM; Kitahata LM
    Conn Med; 1976 Oct; 40(10):672-4. PubMed ID: 975791
    [No Abstract]   [Full Text] [Related]  

  • 53. [Consumption coagulopathy with fibrin rich microcoagula in experimental rabbit hepatitis].
    Reuter C; Müller-Berghaus G
    Verh Dtsch Ges Inn Med; 1973; 79():1340-2. PubMed ID: 4790175
    [No Abstract]   [Full Text] [Related]  

  • 54. [The significance of age for morphological and biochemical changes in galactosamine hepatitis].
    Platt D
    Verh Dtsch Ges Inn Med; 1976; 82 Pt 1():249-51. PubMed ID: 1029185
    [No Abstract]   [Full Text] [Related]  

  • 55. New hepato-protective agents. II. Maleopimaridyl morpholides.
    Danswan GW; Matharu S; Ramm PJ; Taylor JB
    Arzneimittelforschung; 1976; 26(12):2190-2. PubMed ID: 1037272
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of calcium in liver cell damage. Comparative studies with carbon tetrachloride and D-galactosamine.
    Kröner H; Planker M
    Pathol Res Pract; 1980 Nov; 169(3-4):298-303. PubMed ID: 6261229
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Effect of the liver protecting compound ES 914 on D-galactosamine induced experimental hepatitis in the rat].
    Wegmann A; Chariatte N; Renker H; Dittrich A
    Arzneimittelforschung; 1979; 29(1):68-70. PubMed ID: 582121
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A comparison between the morphologic changes in the livers of hamsters and rats after galactosamine treatment and their correlation with altered serum transaminase levels.
    Pickering RW
    Arzneimittelforschung; 1977; 27(9):1684-7. PubMed ID: 579138
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Protective effect of uridine on D-galactosamine-induced deficiency in brain uridine phosphates.
    Popov N; Schmidt S; Matthies H
    Biomed Biochim Acta; 1984; 43(12):1399-404. PubMed ID: 6534378
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [On the pharmacology of piprozoline (author's transl)].
    Herrmann M; Bierkenmayer E; Ganser V; Heldt W; Steinbrecher W
    Arzneimittelforschung; 1977; 27(2b):467-75. PubMed ID: 577406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.